Gene: PDE10A

10846
ADSD2|HSPDE10A|IOLOD|LINC00473|PDE10A19
phosphodiesterase 10A
protein-coding
6q27
Ensembl:ENSG00000112541 MIM:610652 Vega:OTTHUMG00000015986 UniprotKB:Q9Y233
NG_031878.2
PubMed|SNP Mapped
2   ANCO-SNPs
ND|AD
4   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.240e-1 (AD)  6.576e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs9459418chr6:165454303 (GRCh38.p7)C>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs220821chr6:165435750 (GRCh38.p7)A>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DGKH0.82
TMEM1590.773
WDHD10.759
HS6ST20.758
KLHL130.75
B3GNT20.747
RALGPS20.743
RNF1500.741
NETO20.736
GLCE0.734

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CDKN2C-0.417
S100A1-0.417
ASCL1-0.388
HPR-0.387
RLBP1-0.382
NXNL1-0.376
GLI1-0.375
OTX1-0.37
ZIC2-0.366
PYGM-0.36

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00975DipyridamoleSmall Molecule58-32-2ApprovedTarget
DB01113PapaverineSmall Molecule58-74-2Approved|InvestigationalTarget
DB083834,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazoleSmall MoleculeExperimentalTarget
DB083842-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinolineSmall MoleculeExperimentalTarget
DB083862-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinolineSmall MoleculeExperimentalTarget
DB083872-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinolineSmall MoleculeExperimentalTarget
DB083896,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINESmall MoleculeExperimentalTarget
DB083916,7-DIMETHOXY-4-[(3R)-3-(QUINOXALIN-2-YLOXY)PYRROLIDIN-1-YL]QUINAZOLINESmall MoleculeExperimentalTarget
DB08811TofisopamSmall Molecule22345-47-7ApprovedTarget
DB08814TriflusalSmall Molecule322-79-2Approved|InvestigationalTarget
DB00201CaffeineSmall Molecule58-08-2ApprovedTarget
DB09283TrapidilSmall Molecule15421-84-8ApprovedTarget
ID Drug Name Action PubMed
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in decreased expression of PDE10A mRNA19933214
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of PDE10A mRNA"27291303
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of PDE10A mRNA"19114083
C5451212-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline2-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline results in decreased activity of PDE10A protein22947663
C5451212-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline2-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline results in decreased expression of PDE10A mRNA27247380
C5451212-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline2-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline analog binds to PDE10A protein21777010
C5451212-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline2-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline results in decreased expression of PDE10A mRNA27247380
C5451212-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline2-((4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy)methyl)quinoline results in decreased activity of PDE10A protein21777010
C0495842-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine"2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PDE10A mRNA"15215175
C0087454,4'-bisphenol F"4,4'-bisphenol F results in increased expression of PDE10A mRNA"26186136
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of PDE10A mRNA29067470
D000242Cyclic AMPCyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]10373451
D000242Cyclic AMPCyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]10373451
D000242Cyclic AMPDipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]10373451
D000242Cyclic AMPPDE10A protein results in increased hydrolysis of Cyclic AMP10373451
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of PDE10A gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of PDE10A mRNA16483693
C000625385AQ28A compoundAQ28A compound analog binds to PDE10A protein27247380
C000625385AQ28A compound[Dietary Fats co-treated with Dietary Sugars] promotes the reaction [AQ28A compound analog binds to PDE10A protein]27247380
C000625385AQ28A compoundLEP protein affects the reaction [AQ28A compound analog binds to PDE10A protein]27247380
D001280AtrazineAtrazine results in decreased expression of PDE10A mRNA25929836
C487081belinostatbelinostat results in decreased expression of PDE10A mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PDE10A mRNA19770486
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PDE10A mRNA21839799
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of PDE10A mRNA"20382639
D004958Estradiol[bisphenol A co-treated with Estradiol] results in increased expression of PDE10A mRNA26496021
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in increased expression of PDE10A mRNA26496021
C006780bisphenol A[bisphenol A co-treated with Testosterone] results in increased expression of PDE10A mRNA26496021
C006780bisphenol Abisphenol A results in decreased expression of PDE10A mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of PDE10A mRNA29097150
C006780bisphenol Abisphenol A results in increased methylation of PDE10A gene28505145
C018475butyraldehydebutyraldehyde results in decreased expression of PDE10A mRNA26079696
D019256Cadmium ChlorideCadmium Chloride results in decreased expression of PDE10A mRNA26472689
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of PDE10A mRNA26272509
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PDE10A gene20938992
D003024ClozapineClozapine results in increased expression of PDE10A mRNA17266109
D003024ClozapineClozapine results in increased expression of PDE10A mRNA18222493
D003024ClozapineClozapine results in increased expression of PDE10A protein18222493
D003471CuprizoneCuprizone results in increased expression of PDE10A mRNA26577399
C017180decamethrindecamethrin results in increased expression of PDE10A mRNA19017407
D013759DronabinolDronabinol results in increased expression of PDE10A mRNA21955143
D003976DiazinonDiazinon results in decreased expression of PDE10A mRNA17452286
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of PDE10A mRNA27392435
D002945CisplatinCisplatin results in decreased expression of PDE10A mRNA27392435
D004041Dietary Fats[Dietary Fats co-treated with Dietary Sugars] promotes the reaction [AQ28A compound analog binds to PDE10A protein]27247380
D000073417Dietary Sugars[Dietary Fats co-treated with Dietary Sugars] promotes the reaction [AQ28A compound analog binds to PDE10A protein]27247380
C024629dimethyl phthalatedimethyl phthalate affects the expression of PDE10A mRNA26924002
D004176DipyridamoleDipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]10373451
D004176DipyridamoleDipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]10373451
C118739entinostatentinostat results in decreased expression of PDE10A mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
D000431EthanolEthanol results in decreased expression of PDE10A mRNA21955143|2901832
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of PDE10A mRNA29097150
D005419FlavonoidsFlavonoids results in decreased expression of PDE10A mRNA18035473
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PDE10A gene20938992
C069837fullerene C60fullerene C60 results in decreased expression of PDE10A mRNA19167457
D006046Gold[Gold analog co-treated with Mesna] results in decreased expression of PDE10A mRNA22263968
D006152Cyclic GMPCyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]10373451
D006152Cyclic GMPCyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]10373451
D006152Cyclic GMPDipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]10373451
D006152Cyclic GMPPDE10A protein results in increased hydrolysis of Cyclic GMP10373451
D006220HaloperidolHaloperidol results in increased expression of PDE10A mRNA18222493
D006220HaloperidolHaloperidol results in increased expression of PDE10A protein18222493
D017313FenretinideFenretinide results in increased expression of PDE10A mRNA28973697
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of PDE10A mRNA27392435
C544151jinfukangjinfukang results in decreased expression of PDE10A mRNA27392435
D015080Mesna[Gold analog co-treated with Mesna] results in decreased expression of PDE10A mRNA22263968
C042720mercuric bromidemercuric bromide results in decreased expression of PDE10A mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of PDE10A gene20938992
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of PDE10A mRNA"20188158
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in increased expression of PDE10A mRNA24810058
D009020MorphineMorphine results in decreased expression of PDE10A mRNA21955143
C523799MRK 003PDE10A results in decreased susceptibility to MRK 00319903844
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of PDE10A mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of PDE10A mRNA"25554681
C028007nickel monoxidenickel monoxide results in decreased expression of PDE10A mRNA19167457
C029938nickel sulfatenickel sulfate results in increased expression of PDE10A mRNA22714537
D009538NicotineNicotine results in decreased expression of PDE10A mRNA21955143
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of PDE10A mRNA26272509
D010208PapaverinePapaverine results in decreased activity of PDE10A protein21777010
C046012pentanalpentanal results in decreased expression of PDE10A mRNA26079696
D010622PhencyclidinePhencyclidine results in increased expression of PDE10A mRNA17266109
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of PDE10A mRNA26272509
D012402RotenoneRotenone results in increased expression of PDE10A mRNA27900601
C016104sodium bichromatesodium bichromate results in decreased expression of PDE10A mRNA24612858
D053260SootSoot results in increased expression of PDE10A mRNA26551751
D013605T-2 ToxinT-2 Toxin results in decreased expression of PDE10A mRNA26141394
D013739Testosterone[bisphenol A co-treated with Testosterone] results in increased expression of PDE10A mRNA26496021
C004648testosterone enanthatetestosterone enanthate results in increased expression of PDE10A mRNA20463352|2142706
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of PDE10A mRNA22808131
D014212TretinoinTretinoin results in increased expression of PDE10A mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of PDE10A mRNA24935251|2627250
C012589trichostatin Atrichostatin A results in increased expression of PDE10A mRNA24935251
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of PDE10A mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of PDE10A mRNA24383497|2493525
D014635Valproic AcidValproic Acid results in increased expression of PDE10A mRNA24935251
D014635Valproic AcidValproic Acid results in increased expression of PDE10A mRNA23665938
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of PDE10A gene25560391
C025643vinclozolinvinclozolin affects the expression of PDE10A mRNA19015723
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA"27188386
C111237vorinostatvorinostat results in decreased expression of PDE10A mRNA26272509
D015034Zinc OxideZinc Oxide analog results in decreased expression of PDE10A mRNA27215404

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:00041143',5'-cyclic-nucleotide phosphodiesterase activity-TAS10373451  
GO:00041153',5'-cyclic-AMP phosphodiesterase activity-TAS-  
GO:0004118cGMP-stimulated cyclic-nucleotide phosphodiesterase activity-IDA19689430  
GO:0008144drug binding-IEA-  
GO:0030552cAMP binding-IDA19689430  
GO:0030552cAMP binding-NAS15938621  
GO:0030553cGMP binding-NAS15938621  
GO:0046872metal ion binding-IEA-  
GO:00475553',5'-cyclic-GMP phosphodiesterase activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006198cAMP catabolic process-IEA-  
GO:0007186G-protein coupled receptor signaling pathway-TAS-  
GO:0010738regulation of protein kinase A signaling-IEA-  
GO:0043949regulation of cAMP-mediated signaling-IEA-  
GO:0046069cGMP catabolic process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005829cytosol-TAS-  
GO:0016020membrane-IEA-  
GO:0043204perikaryon-IEA-  
KEGG ID KEGG Term
hsa00230Purine metabolism
Reactome ID Reactome Term Evidence
R-HSA-109582HemostasisTAS
R-HSA-162582Signal TransductionTAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-388396GPCR downstream signallingTAS
R-HSA-392154Nitric oxide stimulates guanylate cyclaseTAS
R-HSA-418346Platelet homeostasisTAS
R-HSA-418457cGMP effectsTAS
R-HSA-418555G alpha (s) signalling eventsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28267149Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study. (2017 Mar 7)Boden RTransl Psychiatry
25683181Common genetic variants associated with thyroid function may be risk alleles for Hashimoto's disease and Graves' disease. (2015 Feb 14)Campbell PClin Endocrinol (Oxf)
24782725Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawal. (2014)Logrip MLFront Integr Neurosci
22205951Genome-wide association study in bipolar patients stratified by co-morbidity. (2011)Kerner BPLoS One